Health · 1 sources covering this

STAT+: Pharmalittle: We’re reading about a setback for Eyepoint, a win for Amylyx, and more

Eyepoint disclosed that a Phase 3 trial of its experimental treatment for a common cause of age-related blindness fell short of its primary goal

Share:X WhatsApp Reddit Facebook LinkedIn Open ↗

Coverage spectrum

0 L · 1 C · 0 R

How 1 sources are covering this

STATCenter·1h ago
STAT+: Pharmalittle: We’re reading about a setback for Eyepoint, a win for Amylyx, and more
Eyepoint disclosed that a Phase 3 trial of its experimental treatment for a common cause of age-related blindness fell short of its primary goal
Read at STAT →

Embed this bias spectrum on your site

Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.

<iframe
  src="https://statesidedaily.com/embed/cluster/f199dedc3b2af9eee6c4f4e72727549b41dd645e"
  width="100%" height="320"
  style="border:0;max-width:680px"
  loading="lazy"
  title="STAT+: Pharmalittle: We&#8217;re reading about a setback for Eyepoint, a win for Amylyx, and more"></iframe>

STAT+: Pharmalittle: We’re reading about a setback for Eyepoint, a win for Amylyx, and more

How 1 sources are covering this

STAT+: Pharmalittle: We’re reading about a setback for Eyepoint, a win for Amylyx, and more

More from Health

STAT+: Government workers feel the squeeze on health care

Kindergarten vaccine exemptions are climbing

STAT+: Prominent AI startup rolls out virtual cell model in race to speed up science

STAT+: Amylyx endocrine drug succeeds in pivotal study

Reader

Trust & legal

Across the network

How 1 sources are covering this

STAT+: Pharmalittle: We&#8217;re reading about a setback for Eyepoint, a win for Amylyx, and more

More from Health

STAT+: Government workers feel the squeeze on health care

Kindergarten vaccine exemptions are climbing

STAT+: Prominent AI startup rolls out virtual cell model in race to speed up science

STAT+: Amylyx endocrine drug succeeds in pivotal study

Reader

Trust & legal

Across the network

STAT+: Pharmalittle: We’re reading about a setback for Eyepoint, a win for Amylyx, and more